ToolGen Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
81
- Stock Symbol
-
199800
- Investments
-
4
- Share Price
-
$21.88
- (As of Friday Closing)
ToolGen General Information
Description
ToolGen Inc is a biotechnology company, which focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified, gRNA/Cas9, and recombinant Cas9 protein, which offers ready-to-use reagents for genome engineering experiments. The company also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services.
Contact Information
Website
www.toolgen.comCorporate Office
- 8th Floor, 172 Magokjungang-ro
- Gangseo-gu
- Seoul, 07789
- South Korea
Corporate Office
- 8th Floor, 172 Magokjungang-ro
- Gangseo-gu
- Seoul, 07789
- South Korea
ToolGen Stock Performance
As of 13-Nov-2026, ToolGen’s stock price is $21.88. Its current market cap is $214M with 9.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $21.88 | $22.07 | $20.25 - $94.53 | $214M | 9.8M | 23.8K | -$3.02 |
ToolGen Financials Summary
As of 30-Jun-2026, ToolGen has a trailing 12-month revenue of $1.26M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 201,312 | 337,892 | 211,905 | 401,667 |
| Revenue | 1,259 | 918 | 653 | 844 |
| EBITDA | (26,043) | (24,762) | 6,040 | (32,463) |
| Net Income | (26,961) | (25,833) | 4,567 | (32,384) |
| Total Assets | 33,255 | 42,816 | 51,242 | 72,517 |
| Total Debt | 109 | 1,213 | 9,514 | 46,894 |
ToolGen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ToolGen Comparisons
Industry
Financing
Details
ToolGen Competitors (74)
One of ToolGen’s 74 competitors is Integrated DNA Technologies, a Formerly PE-Backed company based in Coralville, IA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Integrated DNA Technologies | Formerly PE-Backed | Coralville, IA | ||||
| CD Genomics | Corporation | Shirley, NY | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| MeiraGTx | Formerly VC-backed | New York, NY | ||||
| Protobios | Corporation | Tallinn, Estonia |
ToolGen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ToolGen Patents
ToolGen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025135916-A1 | Cas9 protein variant with low immunogenicity | Inactive | 22-Dec-2023 | ||
| WO-2026127237-A1 | Method for editing pepper gene by using tobacco rattle virus-based vector | Pending | 14-Dec-2023 | ||
| WO-2025110693-A1 | Corn plant having herbicide resistance trait through base-editing of epsps gene, and method for producing same | Inactive | 21-Nov-2023 | ||
| WO-2024262920-A1 | Method for delivery of crispr/cas9 into microspores of plant and plant redifferentiation | Inactive | 20-Jun-2023 | ||
| WO-2024253421-A1 | Hemocompatible mesenchymal stem cell, method for preparing same, and use thereof | Inactive | 09-Jun-2023 | C12N5/0662 |
ToolGen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ToolGen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ToolGen Investments (4)
ToolGen’s most recent deal was a Secondary Transaction - Private with Ngene Therapeutics. The deal was made on 18-Dec-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ngene Therapeutics | 18-Dec-2020 | Secondary Transaction - Private | Biotechnology | ||
| ToolGen (Osong Advanced Medical Complex Land in Cheongju, South Korea) | 19-Oct-2017 | Corporate Asset Purchase | Buildings and Property | ||
| Royal D&L (123.51 Square Meters of Land and 512.23 Square Meters of Building in Seoul, South Korea) | 22-Jul-2015 | Corporate Asset Purchase | Buildings and Property | ||
| Ngene Therapeutics | Joint Venture | Biotechnology |
ToolGen ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
ToolGen FAQs
-
When was ToolGen founded?
ToolGen was founded in 1999.
-
Where is ToolGen headquartered?
ToolGen is headquartered in Seoul, South Korea.
-
What is the size of ToolGen?
ToolGen has 81 total employees.
-
What industry is ToolGen in?
ToolGen’s primary industry is Biotechnology.
-
Is ToolGen a private or public company?
ToolGen is a Public company.
-
What is ToolGen’s stock symbol?
The ticker symbol for ToolGen is 199800.
-
What is the current stock price of ToolGen?
As of 13-Nov-2026 the stock price of ToolGen is $21.88.
-
What is the current market cap of ToolGen?
The current market capitalization of ToolGen is $214M.
-
What is ToolGen’s current revenue?
The trailing twelve month revenue for ToolGen is $1.26M.
-
Who are ToolGen’s competitors?
Integrated DNA Technologies, CD Genomics, Regenxbio, MeiraGTx, and Protobios are some of the 74 competitors of ToolGen.
-
What is ToolGen’s annual earnings per share (EPS)?
ToolGen’s EPS for 12 months was -$3.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
